Positions

1. Professor Emeritus, Duke University School of Medicine (2013–2024).
2. Director/Senior Researcher, Institute of Cancer Prevention and Treatment, Guangdong-Hong Kong-Macao Greater Bay Area Precision Medicine Institute (Guangzhou).
3. Researcher, Fudan University Cancer Hospital.

Education

• MD, Nanjing Medical University (1983).
• MSc (Toxicology), China CDC (1986).
• PhD (Epidemiology), Johns Hopkins University (1993).

Previous Appointments

• Tenured Professor, University of MD Anderson Cancer Center (1993–2013).
• Tenured Professor & Associate Director, Duke Cancer Institute (2013–2024).

Research Focus

• Molecular epidemiology of cancer, emphasizing genetic susceptibility biomarkers, environmental carcinogenesis, and cancer survival via genome-wide association studies
  (GWAS).
• Explores etiology, prevention, and prognosis of lung, gastrointestinal, prostate, breast, and ovarian cancers. Pioneered insights into age-related DNA repair dysfunction as
  a driver of carcinogenesis (e.g., skin, lung, oral cancers), informing risk stratification and therapeutic strategies.

Key Achievements

• Clarified mechanisms linking low cellular DNA repair capacity to population-level cancer risk.
• Founding Editor-in-Chief, Cancer Medicine (Wiley); editorial roles in multiple journals.
• NIH grant reviewer; 600+ peer-reviewed publications (H-index >100, citations >40,000). Publications & Leadership:
• Authored seminal work in Nature Genetics. JNCI, and Cancer Research.
• Frequent speaker at international oncology conferences; advisor to global cancer consortia